The U.S. Food and Drug Administration (FDA) recently approved a new astigmatism-correcting intraocular lens (IOL) for use in cataract surgery. The new lens, called the AcrySof IQ Toric IOL, is manufactured by Alcon and is now available for use by cataract surgeons in the United States.
In addition to having a toric design to correct astigmatism, the new premium IOL also has aspheric curves to reduce a common post-surgical optical error called spherical aberration. By reducing spherical aberration, the AcrySof IQ Toric IOL is designed to improve image quality and contrast sensitivity for better night driving vision and sharper vision overall.
In a clinical trial required by the FDA prior to approval, among 37 patients who had the IOL implanted bilaterally for the treatment of cataracts and astigmatism, 98 percent did not need prescription eyeglasses for distance vision six months after surgery. Also, the lens continued to show good rotational stability when checked one year after surgery.
According to Alcon, the AcrySof IQ Toric IOL is a good choice for any patient undergoing cataract surgery who has 0.75 diopter (D) or more corneal astigmatism prior to surgery. The IOL corrects up to 2.50 D of astigmatism, and it can be combined with a procedure called limbal relaxing incisions to correct even higher amounts of astigmatism.
Like other premium IOLs, the AcrySof IQ Toric IOL costs more than a conventional monofocal intraocular lens and will increase your cataract surgery cost. For details, consult a cataract surgeon near you.